INM · InMed Pharmaceuticals Inc.

InMed Pharmaceuticals Inc. faces a critical compliance challenge with Nasdaq Listing Rule 5550(a)(2) after its common shares' closing bid price fell below the $1.00 minimum for 30 consecutive trading days ending March 26, 2026. The notice, dated March 27, 2026, provides a 180-calendar-day grace period to remedy this by sustaining a $1.00+ closing price over 10 consecutive business days. Trading continues uninterrupted on the Nasdaq Capital Market under 'INM', contingent on other listing standards. This development signals potential vulnerability in shareholder value and market perception, as sustained low pricing often reflects broader concerns. Should initial compliance fail, eligibility for a second 180-day extension hinges on satisfying market value of publicly held shares and other initial standards, with a commitment to cure—potentially through a reverse stock split, which could dilute perception without addressing fundamentals. Nasdaq staff may deny extension if cure seems unattainable, leading to delisting proceedings. An appeal to the Hearings Panel offers recourse but suspends trading immediately, heightening uncertainty. The company's proactive monitoring and option exploration underscore intent to mitigate delisting risk, yet success remains unassured amid forward-looking cautions on outcomes.